SCHEMBL3789614

SCHEMBL3789614

CCCCc1csc2ccccc12

nearest known ligand 0.58

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 2/20 0.58
IDO1 P14902 1/20 0.50
ALDH1A1 P00352 2/20 0.48
CHRNA7 P36544 1/20 0.46
SMN1; SMN2 Q16637 5/20 0.45
CRHBP P24387 1/20 0.45
CRHR2 Q13324 1/20 0.45
CA1 P00915 1/20 0.45
CA2 P00918 1/20 0.45
MTNR1A P48039 2/20 0.43
DRD2 P14416 2/20 0.43
SLC6A4 P31645 1/20 0.43
MAPT P10636 1/20 0.43
TP53 P04637 1/20 0.42
RXFP1 Q9HBX9 1/20 0.42
HPGD P15428 1/20 0.41
PTPN1 P18031 1/20 0.40
DRD4 P21917 1/20 0.40
DRD3 P35462 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL368354 0.95 CYP2A6 (0.56) CYP2A6IDO1ALDH1A1CHRNA7SMN1; SMN2
SCHEMBL9347766 0.93 CYP2A6 (0.55) CYP2A6IDO1ALDH1A1CHRNA7SMN1; SMN2
SCHEMBL9347729 0.93 CYP2A6 (0.55) CYP2A6IDO1ALDH1A1CHRNA7SMN1; SMN2
SCHEMBL91191 0.89 CYP2A6 (0.62) CYP2A6IDO1ALDH1A1CHRNA7SMN1; SMN2
SCHEMBL6690187 0.82 DRD2 (0.52) CYP2A6ALDH1A1CHRNA7SMN1; SMN2CRHBP
SCHEMBL5546079 0.81 CYP2A6 (0.58) CYP2A6IDO1ALDH1A1CHRNA7SMN1; SMN2
SCHEMBL79170 0.81 CYP2A6 (0.69) CYP2A6IDO1ALDH1A1CHRNA7SMN1; SMN2
SCHEMBL81236 0.81 CYP2A6 (0.58) CYP2A6IDO1ALDH1A1CHRNA7SMN1; SMN2
SCHEMBL5235492 0.81 CYP2A6 (0.67) CYP2A6IDO1ALDH1A1CHRNA7SMN1; SMN2
SCHEMBL10670791 0.81 IDO1 (0.54) CYP2A6IDO1ALDH1A1CHRNA7SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11193157-B2 Processes using amino acid dehydrogenases and ketoreductase-based cofactor regenerating system CODEXIS, INC. (US) 2021-12-07 US disclosed
US-20200181672-A1 PROCESSES USING AMINO ACID DEHYDROGENASES AND KETOREDUCTASE-BASED COFACTOR REGENERATING SYSTEM INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT 2020-06-11 US disclosed
US-10016401-B2 Histone demethylase inhibitors CELGENE QUANTICEL RESEARCH, INC. (US) 2018-07-10 US disclosed
US-9871211-B2 Electroactive materials EI DU PONT DE NEMOURS AND COMPANY (US) 2018-01-16 US disclosed
US-20170338423-A9 ELECTROACTIVE MATERIALS E I DU PONT DE NEMOURS AND COMPANY (US) 2017-11-23 US disclosed
US-20170326116-A1 HISTONE DEMETHYLASE INHIBITORS CELGENE QUANTICEL RES INC (US) 2017-11-16 US disclosed
US-7645400-B2 Composition containing carbon nanotubes having a coating MITSUBISHI RAYON CO., LTD. (JP) 2010-01-12 US disclosed
US-20090321688-A1 Carbon Nanotube Composition, Composite Having a Coated Film Composed of the Same, and Their Production Methods MITSUBISHI RAYON CO., LTD. (JP) 2009-12-31 US disclosed
US-20060052509-A1 Composition containing carbon nanotubes having coating thereof and process for producing them MITSUBISHI RAYON CO., LTD. (JP) 2006-03-09 US disclosed
WO-2001007431-A2 BENZOTHIOPHENE DERIVATIVES ELI LILLY AND COMPANY (US) 2001-02-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10016401-B2 Histone demethylase inhibitors KDM1B, KDM1A, KDM5A CYP2A6 2111/4885IDO1 371/4885ALDH1A1 437/4885
US-20170338423-A9 ELECTROACTIVE MATERIALS KCNN4, RCOR3, HCN4 CYP2A6 3076/4885IDO1 2180/4885ALDH1A1 3134/4885
US-20170326116-A1 HISTONE DEMETHYLASE INHIBITORS KDM1B, KDM1A, KDM5A CYP2A6 2111/4885IDO1 371/4885ALDH1A1 437/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.